Grifols Achieves Positive Topline Results from Phase 3b Study of its Fibrin Sealant to Treat Surgical Bleeding in Pediatric Patients

Having met all primary and secondary endpoints, the study is expected to facilitate regulatory approval to expand the use of the FS-based biosurgery treatment, currently indicated for adults, to children and adolescents as well notes Grifols.